50-32-222. Specific dangerous drugs included in Schedule I. Schedule I consists of the drugs and other substances, by whatever official, common, usual, chemical, or brand name designated, listed in this section.
     (1) Opiates. Unless specifically excepted or listed in another schedule, any of the following opiates, including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation:
     (a) acetyl-alpha-methylfentanyl;
     (b) acetylmethadol;
     (c) allylprodine;
     (d) alphacetylmethadol;
     (e) alphameprodine;
     (f) alphamethadol;
     (g) alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine);
     (h) benzethidine;
     (i) betacetylmethadol;
     (j) beta-hydroxyfentanyl;
     (k) beta-hydroxy-3-methylfentanyl;
     (l) betameprodine;
     (m) betamethadol;
     (n) betaprodine;
     (o) clonitazene;
     (p) dextromoramide;
     (q) diampromide;
     (r) diethylthiambutene;
     (s) difenoxin;
     (t) dimenoxadol;
     (u) dimepheptanol;
     (v) dimethylthiambutene;
     (w) dioxaphetyl butyrate;
     (x) dipipanone;
     (y) ethylmethylthiambutene;
     (z) etonitazene;
     (aa) etoxeridine;
     (bb) furethidine;
     (cc) hydroxypethidine;
     (dd) ketobemidone;
     (ee) levomoramide;
     (ff) levophenacylmorphan;
     (gg) 3-methylfentanyl;
     (hh) 3-methylthiofentanyl;
     (ii) morpheridine;
     (jj) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
     (kk) noracymethadol;
     (ll) norlevorphanol;
     (mm) normethadone;
     (nn) norpipanone;
     (oo) para-fluorofentanyl;
     (pp) PEPAP(1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
     (qq) phenadoxone;
     (rr) phenampromide;
     (ss) phenomorphan;
     (tt) phenoperidine;
     (uu) piritramide;
     (vv) proheptazine;
     (ww) properidine;
     (xx) propiram;
     (yy) racemoramide;
     (zz) thiofentanyl;
     (aaa) tilidine; and
     (bbb) trimeperidine.
     (2) Opium derivatives. Unless specifically excepted or listed in another schedule, any of the following opium derivatives, its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
     (a) acetorphine;
     (b) acetyldihydrocodeine;
     (c) benzylmorphine;
     (d) codeine methylbromide;
     (e) codeine-n-oxide;
     (f) cyprenorphine;
     (g) desomorphine;
     (h) dihydromorphine;
     (i) drotebanol;
     (j) etorphine;
     (k) heroin;
     (l) hydromorphinol;
     (m) methyldesorphine;
     (n) methyldihydromorphine;
     (o) morphine methylbromide;
     (p) morphine methylsulfonate;
     (q) morphine-n-oxide;
     (r) myrophine;
     (s) nicocodeine;
     (t) nicomorphine;
     (u) normorphine;
     (v) pholcodine; and
     (w) thebacon.
     (3) Hallucinogenic substances. Unless specifically excepted or listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following hallucinogenic substances or any of its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
     (a) 3,4-methylenedioxy amphetamine;
     (b) 3,4-methylenedioxymethamphetamine (MDMA);
     (c) 5-methoxy-3,4-methylenedioxy amphetamine;
     (d) 3,4,5-trimethoxy amphetamine;
     (e) bufotenine;
     (f) doet (2,5-dimethoxy-4-ethalamphetamine);
     (g) diethyltryptamine;
     (h) dimethyltryptamine;
     (i) 4-methyl-2,5-dimethoxy-amphetamine;
     (j) ibogaine;
     (k) lysergic acid diethylamide;
     (l) marijuana;
     (m) mescaline;
     (n) parahexyl;
     (o) peyote;
     (p) PCE (N-ethyl-1-phenylcyclohexylamine);
     (q) PHP 1-(1-phenylcyclohexyl)pyrrolidine (pcp analog);
     (r) n-ethyl-3-piperidyl benzilate;
     (s) n-methyl-3-piperidyl benzilate;
     (t) psilocybin;
     (u) psilocyn;
     (v) tetrahydrocannabinols;
     (w) 2,5-dimethoxyamphetamine;
     (x) 4-bromo-2,5-dimethoxy-amphetamine;
     (y) 4-methoxyamphetamine;
     (z) ethylamine analog of phencyclidine;
     (aa) pyrrolidine analog of phencyclidine; and
     (bb) thiophene analog of phencyclidine.
     (4) Depressants. Unless specifically excepted or listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substance having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
     (a) mecloqualone; and
     (b) methaqualone.
     (5) Stimulants. Unless specifically excepted or listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:
     (a) fenethylline; and
     (b) n-ethylamphetamine.
     (6) For purposes of subsection (3) only, the term "isomer" includes the optical, position, and geometric isomers.
     (7) If prescription or administration is authorized by the Federal Food, Drug and Cosmetic Act, then any material, compound, mixture, or preparation containing tetrahydrocannabinols listed in subsection (3) shall automatically be rescheduled from Schedule I to Schedule II.

     History: En. Sec. 5, Ch. 412, L. 1973; R.C.M. 1947, 54-305; amd. Sec. 1, Ch. 320, L. 1979; amd. Sec. 1, Ch. 141, L. 1983; amd. Sec. 1, Ch. 36, L. 1991.